Peripheral arterial disease (PAD) is a common manifestation of atherosclerotic vascular disease and the incidence of infrapopliteal PAD continues to rise in the population. The historical experience with surgical and endovascular interventions for infrapopliteal stenosis was disappointing as operators experienced high rates of early technical failures and procedural complications, coupled with high rates of restenosis in this vascular territory when compared with more proximal vascular beds. While patients with infrapopliteal PAD may be asymptomatic, the majority would ultimately develop intermittent claudication or may also present with critical limb ischemia. In this article, we review the current literature, and discuss some of the technical aspects of endovascular therapy in this vascular bed. We also emphasize the importance of adjunctive evidence-based therapies such as antiplatelet agents, statins, and lifestyle modification such as smoking cessation in this particularly high-risk cohort to optimize clinical outcomes.
Paraskevas KI , Kotsikoris I., Koupidis SA, Giannoukas AD, Mikhailidis DPAnkle-brachial index: a marker of both peripheral arterial disease and systemic atherosclerosis as well as a predictor of vascular events. Angiology.2010;61(6):521-523.
2.
Tziomalos K. , Athyros VG, Karagiannis A., Mikhailidis DPThe role of ankle brachial index and carotid intima-media thickness in vascular risk stratification. Curr Opin Cardiol.2010 ;25(4): 394-398.
3.
Carmona GA, Hoffmeyer P., Herrmann FR, et al. Major lower limb amputations in the elderly observed over ten years: the role of diabetes and peripheral arterial disease. Diabetes Metab. 2005; 31(5):449-454.
Menard MT, Belkin M.Infrapopliteal intervention for the treatment of the claudicant. Semin Vasc Surg. 2007;20(1):42-53.
6.
Norgren L., Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg. 2007;33(suppl 1):S1-S75.
7.
Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. J Am Coll Cardiol . 2006;47(6): 1239-1312.
8.
Karnabatidis D., Katsanos K., Siablis D.Infrapopliteal stents: overview and unresolved issues. J Endovasc Ther.2009;16(suppl1): 1153-1162.
9.
Donaldson MC , Mannick JA, Whittemore ADFemoral-distal bypass with in situ greater saphenous vein. Long-term results using the Mills valvulotome . Ann Surg.1991;213(5):457-464; discussion 464-455.
10.
Rafferty TD , Avellone JC, Farrell CJ, et al. A metropolitan experience with infrainguinal revascularization. Operative risk and late results in northeastern Ohio. J Vasc Surg. 1987;6(4):365-371.
11.
Quinones-Baldrich WJ, Prego AA, Ucelay-Gomez R., et al. Long-term results of infrainguinal revascularization with polytetrafluoroethylene: a ten-year experience. J Vasc Surg. 1992;16(2): 209-217.
12.
Bergamini TM , Towne JB, Bandyk DF, Seabrook GR, Schmitt DDExperience with in situ saphenous vein bypasses during 1981 to 1989: determinant factors of long-term patency. J Vasc Surg.1991;13(1):137-147; ; discussion 148-139.
13.
Schepers A. , Klinkert P., Vrancken Peeters MP, Breslau PJComplication registration in patients after peripheral arterial bypass surgery. Ann Vasc Surg. 2003;17(2):198-202.
14.
Hunink MG, Wong JB, Donaldson MC, Meyerovitz MF, de Vries J., Harrington DPRevascularization for femoropopliteal disease. A decision and cost-effectiveness analysis. JAMA. 1995;274(2):165-171.
15.
Romiti M., Albers M., Brochado-Neto FC, Durazzo AE, Pereira CA, De Luccia N.Meta-analysis of infrapopliteal angioplasty for chronic critical limb ischemia . J Vasc Surg. 2008; 47(5):975-981.
16.
Zhu YQ, Zhao JG, Liu F., et al. Subintimal angioplasty for below-the-ankle arterial occlusions in diabetic patients with chronic critical limb ischemia. J Endovasc Ther.2009;16(5):604-612.
17.
Manzi M., Fusaro M., Ceccacci T., Erente G., Dalla Paola L., Brocco E.Clinical results of below-the knee intervention using pedal-plantar loop technique for the revascularization of foot arteries. J Cardiovasc Surg (Torino). 2009;50(3):331-337.
18.
Paraskevas KI, Giannoukas AD, Kotsikoris I., Mikhailidis DPContrast-induced nephropathy and the vascular patient. Angiology.2010;61(8):721-723.
19.
Ishibashi Y. , Yamauchi M., Musha H., Mikami T., Kawasaki K., Miyake F.Impact of contrast-induced nephropathy and cardiovascular events by serum cystatin C in renal insufficiency patients undergoing cardiac catheterization. Angiology.2010;61(8):724-730.
20.
Sadat U., Walsh SR, Norden AG, Gillard JH, Boyle JRDoes oral N-acetylcysteine reduce contrast-induced renal injury in patients with peripheral arterial disease undergoing peripheral angiography? A randomized-controlled study. Angiology. 2010.
21.
ACT Trial Investigators.Rationale, design, and baseline characteristics of the Acetylcystein for Contrast-Induced nephropaThy (ACT) Trial: a pragmatic randomized controlled trial to evaluate the efficacy of acetylcysteine for the prevention of contrast-induced nephropathy . Trials. 2009;10:38.
22.
Ozhan H., Erden I., Ordu S., et al. Efficacy of short-term high-dose atorvastatin for prevention of contrast-induced nephropathy in patients undergoing coronary angiography . Angiology.2010; 61(7):711-714.
23.
Rysz J., Aronow WS, Stolarek RS, Hannam S., Mikhailidis DP, Banach M.Nephroprotective and clinical potential of statins in dialyzed patients . Expert Opin Ther Targets.2009;13(5):541-550.
24.
Heitmeyer C. , Holscher B., Fobker M., Breithardt G., Hausberg M., Reinecke H.Prognostic value of different laboratory measures of renal function for long-term mortality after contrast media-associated renal impairment. Clin Cardiol . 2010;33(12):E51-E59.
Bradbury AWBypass versus Angioplasty in severe ischaemia of the leg (BASIL) trial in perspective. J Vasc Surg.2010;51(suppl5):1S-4S.
27.
Adam DJ, Beard JD, Cleveland T., et al. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. Lancet. 2005;366(9501):1925-1934.
28.
Schwarten DE , Cutcliff WBArterial occlusive disease below the knee: treatment with percutaneous transluminal angioplasty performed with low-profile catheters and steerable guide wires . Radiology. 1988;169(1):71-74.
29.
Brown KT, Moore ED, Getrajdman GI, Saddekni S.Infrapopliteal angioplasty: long-term follow-up. J Vasc Interv Radiol. 1993; 4(1):139-144.
30.
Hanna GP, Fujise K., Kjellgren O., et al. Infrapopliteal transcatheter interventions for limb salvage in diabetic patients: importance of aggressive interventional approach and role of transcutaneous oximetry. J Am Coll Cardiol. 1997;30(3):664-669.
31.
Dorros G., Jaff MR, Murphy KJ, Mathiak L.The acute outcome of tibioperoneal vessel angioplasty in 417 cases with claudication and critical limb ischemia. Cathet Cardiovasc Diagn. 1998; 45(3):251-256.
32.
Rogers JH, Laird JROverview of new technologies for lower extremity revascularization . Circulation. 2007;116(18): 2072-2085.
33.
Keeling WB, Shames ML, Stone PA, et al. Plaque excision with the Silverhawk catheter: early results in patients with claudication or critical limb ischemia. J Vasc Surg. 2007;45(1):25-31.
34.
Ramaiah V., Gammon R., Kiesz S., et al. Midterm outcomes from the TALON Registry: treating peripherals with SilverHawk: outcomes collection. J Endovasc Ther. 2006;13(5):592-602.
35.
Kandzari DE , Kiesz RS, Allie D., et al. Procedural and clinical outcomes with catheter-based plaque excision in critical limb ischemia. J Endovasc Ther. 2006;13(1):12-22.
36.
McKinsey JF , Goldstein L., Khan HU, et al. Novel treatment of patients with lower extremity ischemia: use of percutaneous atherectomy in 579 lesions. Ann Surg. 2008;248(4):519-528.
37.
Yancey AE, Minion DJ, Rodriguez C., Patterson DE, Endean EDPeripheral atherectomy in TransAtlantic InterSociety Consensus type C femoropopliteal lesions for limb salvage. J Vasc Surg. 2006 ;44(3):503-509.
38.
Zeller T., Rastan A., Sixt S., et al. Long-term results after directional atherectomy of femoro-popliteal lesions. J Am Coll Cardiol. 2006;48(8):1573-1578.
39.
Das TSExcimer laser-assisted angioplasty for infrainguinal artery disease . J Endovasc Ther.2009;16(2suppl2):1198-1104.
40.
Dave RM, Patlola R., Kollmeyer K., et al. Excimer laser recanalization of femoropopliteal lesions and 1-year patency: results of the CELLO registry. J Endovasc Ther. 2009;16(6):665-675.
41.
Bosiers M., Peeters P., Elst FV, et al. Excimer laser assisted angioplasty for critical limb ischemia: results of the LACI Belgium Study. Eur J Vasc Endovasc Surg . 2005;29(6):613-619.
42.
Heuser RRTreatment of lower extremity vascular disease: the Diamondback 360 degrees Orbital Atherectomy System. Expert Rev Med Devices . 2008;5(3):279-286.
43.
Casserly IPOrbital atherectomy - another tool in the art of peripheral arterial intervention. Catheter Cardiovasc Interv.2009;73(3):413-414.
44.
Korabathina R., Mody KP, Yu J., Han SY, Patel R., Staniloae CSOrbital atherectomy for symptomatic lower extremity disease. Catheter Cardiovasc Interv.2010;76(3):326-332.
45.
Safian RD, Niazi K., Runyon JP, et al. Orbital atherectomy for infrapopliteal disease: device concept and outcome data for the OASIS trial. Catheter Cardiovasc Interv.2009;73(3):406-412.
Patlola R., Hebert C., Allie D.Orbital atherectomy in treatment of peripheral arterial occlusive disease below the knee: a large single-center experience. Presented at: Transcatheter Cardiovascular Therapeutics 2009; September 21 -26, 2009; San Francisco, CA .
48.
Siablis D., Karnabatidis D., Katsanos K., et al. Infrapopliteal application of sirolimus-eluting versus bare metal stents for critical limb ischemia: analysis of long-term angiographic and clinical outcome. J Vasc Interv Radiol.2009;20(9):1141-1150.
49.
Werk M., Langner S., Reinkensmeier B., et al. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation. 2008;118(13):1358-1365.
50.
Tepe G., Zeller T., Albrecht T., et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med. 2008;358(7):689-699.
51.
Feiring AJ, Krahn M., Nelson L., Wesolowski A., Eastwood D., Szabo A.Preventing leg amputations in critical limb ischemia with below-the-knee drug-eluting stents: the PaRADISE (PReventing Amputations using Drug eluting StEnts) trial . J Am Coll Cardiol.2010;55(15):1580-1589.
52.
Makam P.BTK stenting in critical limb ischemia: a review of the data and practical techniques for below-the-knee stenting. Endovascular Today . 2010;September:69-72.
53.
Landini L., Leone A., Mikhailidis DPModifying cardiovascular risk factors: newer insights and preventive measures . Curr Pharm Des.2009;15(10):1034-1037.
Sarigianni M., Katsiki N., Mikhailidis DPEffects of combined ezetimibe and simvastatin therapy as compared with simvastatin alone in patients with type 2 diabetes: a prospective randomized double-blind clinical trial: comment on Ruggenenti et al. Diabetes Care. 2010;33:e132; ; author reply e133.
56.
Paraskevas KI, Bessias N., Papas TT, Gekas CD, Andrikopoulos V., Mikhailidis DPDo different vascular risk factors affect all arteries equally?Angiology . 2008;59(4):397-401.
